MIAMI, FL, June 24, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
A New Drug Application for the EE and NERD indications for tegoprazan will be submitted in the fourth quarter of 2025. Topline data were announced from the maintenance phase of a phase 3 trial ...
Eligible patients taking Camzyos in the maintenance phase now only require twice-yearly echocardiogram monitoring. The Food and Drug Administration (FDA) has updated the labeling for Camzyos ® ...
The USS Dwight D. Eisenhower arrived at Norfolk Naval Shipyard on Jan. 8 for a scheduled Planned Incremental Availability period (PIA) — maintenance, repairs and modernization — after completing a ...
--Veru has been granted a meeting with FDA to discuss the Phase 3 clinical program-- MIAMI, FL, June 24, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical ...
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results